Isao Tawara

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2026

Background/Objectives: Autoimmune factor VIII deficiency (AiFVIIID) is a rare disorder that causes severe bleeding. Emicizumab has recently been found to be effective in treating AiFVIIID; however, monitoring with standard coagulation tests presents challenges. Methods: Clot waveform analysis (CWA), which involves CWA-activated partial thromboplastin time (APTT), the CWA-small amount of tissue factor activation assay (sTF/FIXa), and clotting time using a small amount of thrombin (sTT), was used to both diagnose AiFVIIID and monitor emicizumab. Results: CWA-sTT reflects the residual FVIII activity in patients with AiFVIIID. Several tests were employed, including APTT, FVIII activity, CWA, mixing tests with normal plasma, FVIII inhibitor assays, and anti-FVIII antibody activity for the diagnosis of AiFVIID in three cases. However, the sensitivity of APTT reagents to AiFVIID differed between thrombocheck-APTT and APTT-SP. Emicizumab treatment was effective for major bleeding, and anti-FVIII antibody activity could be measured using CWA-sTT. Conclusions: The sensitivity of APTT reagents to AiFVIID varies. CWA-sTT may provide utility in the diagnosis of AiFVIIID. Emicizumab is useful for the treatment of AiFVIID, and anti-FVIII antibody activity can be measured even in patients treated with emicizumab.

Year:

2025

Background: Diagnostic criteria for disseminated intravascular coagulation (DIC) have been established by the Japanese Ministry of Health, Labor, and Welfare (JMHLW), the International Society of Thrombosis Hemostasis (ISTH), and the Japanese Association for Acute Medicine (JAAM). These criteria vary and are complicated, and the cutoff values differ, so a simple and rapid diagnostic approach for DIC is needed. Materials and Methods: The usefulness of the DIC index (prothrombin time-international normalized ratio [PT-INR] x D-dimer/platelet count) for diagnosing DIC and predicting outcomes in 1500 critically ill patients was assessed. Results: The PT-INR, D-dimer level, and DIC index were significantly higher in patients with DIC than in those without DIC, and their platelet count was significantly lower. Receiver operating characteristic (ROC) analyses showed that the diagnostic agreement was the highest for the JMHLW score among the three diagnostic criteria. The PT-INR, D-dimer level, DIC index, and JMHLW, ISTH overt-DIC, and modified JAAM DIC scores were significantly higher in non-survivors than in survivors, and their platelet counts were significantly lower. Although ROC analyses showed that the PT-INR, D-dimer level, platelet count, DIC index, JMHLW, ISTH overt-DIC, and modified JAAM DIC scores were related to the outcome, the cutoff values of the DIC index, and JMHLW, ISTH overt-DIC and modified JAAM DIC scores were low. Conclusions: The DIC index was highly consistent with the three diagnostic criteria for DIC and related outcomes.

Year:

2025

Background Cisplatin‐associated hemolysis is a rare but important adverse effect. Nonimmunological protein adsorption (NIPA) due to erythrocyte membrane modification has been reported as the leading cause of cisplatin‐associated hemolysis. However, limited data exist on cisplatin‐associated immunological hemolysis because of a lack of an established diagnostic method. Here, we used flow cytometry (FCM) to diagnose a patient with cisplatin‐associated immunological hemolysis. Study Design and Methods A 55‐year‐old woman with uterocervical cancer was treated with weekly cisplatin monotherapy (40 mg/m 2 ). She had no previous transfusion and medication history, nor any significant family history. On the 26th day after cisplatin administration, severe hemolysis was noted. Her red blood cells (RBCs) and sera were evaluated by direct antiglobulin test (DAT) and indirect antiglobulin test (IAT), respectively. To explore immunological reactions for cisplatin‐treated RBCs, we attempted FCM using cisplatin‐treated and ‐untreated RBCs. After incubating conditioned RBCs with the patient's serum or healthy donor serum, we evaluated their fluorescent intensity by fluorescein isothiocyanate (FITC)‐conjugated anti‐human immunoglobulin (Ig) G antibodies. Results The patient's DAT was positive, and an IAT using her plasma was positive for cisplatin‐treated RBCs. FCM using cisplatin‐treated RBCs revealed that the patient's serum had higher FITC intensity than the donor's serum, indicating the existence of cisplatin‐treated RBC‐specific IgGs in patient's serum. Conclusion Here, we report a rare case of a patient with hemolysis diagnosed using FCM to identify specific antibodies against cisplatin‐treated RBCs. NIPA and immunological mechanisms may contribute to hemolysis onset during cisplatin treatment.

Year:

2023

Collaborators (5)

Tetsuya Nosaka

Professor

Mie university

JAPAN
View details

Motomu Shimaoka

Professor and Chair

Mie university

JAPAN
View details

Yuka Sugimoto

Associate professor

Mie university

JAPAN
View details

Hideo Wada

Professor

-

JAPAN
View details

Keiki Nagaharu

Lund University

SWEDEN
View details